Victoria DPI Fast-Tracks Agribioscience Research with Genedata Expressionist Refiner MS
Mass spectrometry solution for high-throughput proteomics and metabolomics data will showcase at 27th Montreux Symposium on LC/MS
November 10, 2010
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced Genedata Expressionist® Refiner MS for mass spectrometry will be used in agribioscience research by Australia's Victorian Department of Primary Industries (DPI). DPI's Biosciences Research Division works to improve plant and animal productivity and fight disease in animals and plants by identifying plant pathogens as well as resistance to animal parasites. Refiner MS, with its advanced visualization capabilities, will help DPI scientists analyze huge proteomics and metabolomics datasets at any stage of data processing. Genedata Expressionist Refiner MS will be demonstrated at the 27th Montreux Symposium on LC/MS (Booth 6; Nov. 10–12).
"We focus on the systems biology of agriscience and Genedata Expressionist helps us make sense of all the raw data made available to us through proteomics and metabolomics," said Dr. Ben Cocks, research director for the Biosciences Research Division. "With Refiner MS we're analyzing hundreds of one-gigabyte LC/MS files. This is a huge advantage of Refiner MS as the open source software we used prior to Genedata was incapable of handling very large datasets, which are requisite for thorough research." The Biosciences Research Division is part of a large research community at DPI and Cocks notes, "The Genedata solution is instrument-independent and manufacturer-agnostic, contributing to a low total cost of ownership while advancing an enterprise-wide application."
Refiner MS is a module within the Genedata Expressionist enterprise system for biomarker discovery and molecular profiling. The system is a single-point-of-access for experimental, proprietary, and public data, including sample information, raw and pre-processed data, and analysis results with reports and documentation. Refiner MS functionality can be extended along the R&D workflow with additional Refiner modules as well as Genedata Analyst™ for sample-centric data organization, statistical analysis, biological interpretation, prediction, and decision support.
No Black Box Solution
"The statistics underlying Refiner MS are pretty solid," said Dr. Simone Rochfort, principal research scientist for Discovery Technologies. "At each step you can visualize your data, which allows you to understand what the software is doing to your data—so Refiner MS is no black box solution." Rochfort projects that Refiner MS visualization capabilities will help promote more cross-platform integration and collaboration among research groups at DPI. "Currently, we have a particular muscle system of interest. We've done some metabolomics and proteomics on this system and all these data will be linked within Genedata Analyst. Genedata visualization tools will allow us to this easily in a manner that makes statistical sense." Analysis results can be accessed by researchers who can identify proteins of interest or metabolites correlating to those proteins.
"We're honored to have Genedata solutions become an integral part of the DPI's mission to maintain a competitive, productive, and sustainable farm business for the people of Victoria and beyond," said Dr. Othmar Pfannes, CEO of Genedata. "Our partnership with DPI also underscores Genedata unflagging commitment to its global customers regardless of their location."
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.